Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, I. Thalmann, Sabine Schmatloch et al.|Journal of Clinical Oncology|2024Cited by 11
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Theodoros Foukakis, Ioannis Zerdes et al.|Breast Cancer Research and Treatment|2024Cited by 6
Omission of postoperative radiotherapy after breast-conserving surgery in low-risk breast cancerSofia Palmér, Kenneth Villman, Antonios Valachis et al.|JNCI Journal of the National Cancer Institute|2024Cited by 2
Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trialKang Wang, Theodoros Foukakis, Yajing Zhu et al.|Cancer Research|2023Cited by 0